We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Rapid POC Test Developed to Detect Influenza

By LabMedica International staff writers
Posted on 22 May 2017
Addressing the perennial threat of a major flu pandemic, researchers have developed fast, easy-to-use point-of-care (POC) diagnostic test for influenza that could head off rapid spread of the virus during an outbreak. More...
Preliminary clinical testing of the prototype device were encouraging.

Existing rapid diagnostic tests can help with diagnoses but require multiple processing steps that still need to be performed with lab equipment in specialized facilities. Prof. Paul Yager, University of Washington, and colleagues set out to create a simpler, low-cost device that overcomes these difficulties. The researchers incorporated multiple steps of influenza detection – viral lysis, target protein capture, labeling, rinsing, and an enzyme-driven color change – into one device. A user swabs the inside of a patient’s nose, inserts the swab into the device, and twirls it for 10 seconds to release the virus. The device takes care of the rest. After about 35 minutes (total test time from device initiation to result), it produces a visual readout that can be seen with the naked eye and recorded with a smartphone camera. The materials and reagents for one of these single-use disposable devices cost less than USA 6.

The test is based on a sandwich immunoassay for influenza virus nucleoprotein and runs in a 2-dimensional paper network format. The device contains all reagents and required no dedicated instruments.

The researchers trained clinical staff at Seattle Children’s Hospital to use the prototype device to detect influenza A and B in those specimens. 25 patients were tested during a flu outbreak. Influenza A was detected, with accuracy of ∼70% based on in-house qRT-PCR influenza A as a gold-standard comparison. The ratio of valid to total completed device runs yielded a success rate of 92%, and the negative predictive value for both the influenza A and B assay was 81%. The ability to diagnose respiratory infections rapidly and close to the patient was well received by hospital staff, inspiring further optimization of device function.

The study, by Huang S et al, was published April 26, 2017, in the journal Analytical Chemistry.


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.